

10- 12 December 2024 | Riyadh Front Exhibition & Convention Center Riyadh, Saudi Arabi

Key stats – Saudi Arabia’s pharmaceutical market

“This will be one of the largest healthcare transformations in the world in terms of number of centres, size of population served, and complexity”

Prof. Ahmed Aljedai, Assistant Deputy Minister, MOH, KSA



Largest pharma market in the Middle East
(\$12.1billion USD in 2023)



Steadily growing market with a compound annual growth rate (CAGR) of 5.2%



Significant demand for medications like diabetes, cardiovascular issues, and cancer



Largest market for prescription drugs in the GCC (\$11.05Bn)




KSA imports over 81% of the generic drugs and **94%** of medical devices & equipment

VISION 2030

Saudi government plans to promote private sector participation to reach 65% by 2030 under Vision 2030, with many hospitals and healthcare clinics targeted for privatization.



Saudi pharma market value



Key market players:

In 2020, Global giants Pfizer, Sanofi, and Novartis make up the top three spots. List also includes AstraZeneca, GSK and Abbott, but regional players Tabuk, Spimako and Hikma Pharma are also represented in the top 10.

For more **information on the Saudi pharma market** and to learn about opportunities at CPHI Middle East, please visit:

cphi.com/middle-east